Print this page
 Email this page

 Connect with UMMC on:
 Twitter
 Facebook
 YouTube
iPhone

 Share this page:

Bookmark and Share

Home > Medical Reference > Encyclopedia (English)

Toggle: English / Spanish

 

Video details

[ Flash player icon ] Please install flash player to see this video.

Related Content


 

CA-125 - Overview

Definition of CA-125:

CA-125 is a test used to evaluate ovarian cancer treatment.

How the test is performed:

Blood is typically drawn from a vein, usually from the inside of the elbow or the back of the hand. The site is cleaned with germ-killing medicine (antiseptic). The health care provider wraps an elastic band around the upper arm to apply pressure to the area and make the vein swell with blood.

Next, the health care provider gently inserts a needle into the vein. The blood collects into an airtight vial or tube attached to the needle. The elastic band is removed from your arm. Once the blood has been collected, the needle is removed, and the puncture site is covered to stop any bleeding.

How to prepare for the test:

No preparation is necessary.

How the test will feel:

When the needle is inserted to draw blood, some people feel moderate pain, while others feel only a prick or stinging sensation. Afterward, there may be some throbbing.

Why the test is performed:

CA-125 is a protein that is found more in ovarian cancer cells than in other cells. This protein enters the bloodstream and can be measured by a blood test. There are two CA-125 tests: a first generation test and a second generation test. The second generation test is now more widely used and is generally more accurate.

The test is often used to follow women who have already been diagnosed with ovarian cancer. In these cases, the CA-125 is a very good indicator of whether a patient is responding to treatment, and whether a patient remains in remission after treatment. In general, the CA-125 is not a good test to screen healthy women for ovarian cancer.

  • Reviewed last on: 6/10/2008
  • James R. Mason, MD, Oncologist, Director, Blood and Marrow Transplantation Program and Stem Cell Processing Lab, Scripps Clinic, Torrey Pines, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

References

Dann RB, et al. Strategies for ovarian cancer prevention. Obstet Gynecol Clin North Am. 2007;34(4):667-686.

Goonewardene TI, et al. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8(9):813-821.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com